ASTREMIHA THERAPEUTICS develops
a new class of broad-spectrum antivirals
Discover, Prevent and Cure
About Us
Our Team
Teams & Investors: Our team embodies four essential qualities: Ambition, Creativity, Talent, and a Goal-oriented mindset.
Founders:
Mireille Laforge
PhD, HDR, CR CNRS, CSO
Founder
I discovered broad-spectrum antiviral drugs with immune modulation and research immunometabolism's role in infectious diseases and neurodevelopmental disorders to develop new diagnostic and treatment strategies.
Pierre Gressens
MD, PhD, DRE INSERM, Co-CSO
Co-Founder
Director of research and clinical initiatives focusing on neurodevelopmental disorders and treatments related to premature birth, with over 400 published articles, contributing significantly to medical science.
Raphael de Saint Exupéry
Innovation Management
Co-Founder
MSc in Management, specializing in Data Analysis, Innovation Management, and Pharma Consulting, offering expertise in strategic decision-making and innovative solutions within the pharmaceutical and healthcare industries.
Board Members:
François Rossier
CEO
François Rossier brings diverse professional expertise from defense and interministerial roles to his current positions in private sector as Key Account Director for France and Switzerland, alongside volunteering as Secretary General of Ailes de France Foundation and ambassador for Institut Robert Debré Brain Child Project.
Isabelle Hilali
Independent Administrator
Combines extensive global executive experience in aerospace, mobile, internet, healthcare, and education sectors with board memberships and scientific committee roles in health and AI. Her leadership has driven innovation and strategic growth, particularly in international markets, contributing significantly to technological advancements and healthcare improvements.
Thierry Roussel
Independent Administrator
Entrepreneur and executive, co-founded Direct Energie and Senioradom, sold multiple companies, now invests in energy, support for vulnerable people, food, and agriculture. His leadership has been instrumental in driving growth and innovation, and he continues to influence the energy and healthcare sectors through strategic investments and advisory roles.
Scientific Advisory Board Members:
Philippe Rouanet De Berchoux
Medical Advisor
General practitioner and former Armed Forces Health Service director, specializes in strategic health leadership and crisis management.
Bruno Villoutreix
Drug Development Advisor
Research director at INSERM, specializes in AI-driven drug development and therapeutic protein design, with notable contributions to cancer treatment and drug repurposing.
Michael Spedding
Drug Development Advisor
President of Spedding Research Solutions SAS, focuses on ALS and long COVID drug development, with a prolific pharmacology career, over 230 publications, and 20+ patents.
Nicolas Chomont
Scientific Advisor, Immunopathology/Infectiology
Associate Professor at the University of Montreal, researches HIV latency and eradication, focusing on the persistence of HIV-infected cells and T lymphocyte proliferation.
Vincent Calvez
Scientific Advisor, Infectiology/Viral Infection
Professor of Clinical Virology at Sorbonne University, leads the Virology Department at Pitié-Salpêtrière Hospital, directs the ANRS Virology Network, and has significant contributions in antiviral and oncology therapeutics.
Our Research
The anti-caspase inhibitor Q-VD-OPH prevents AIDS disease progression in SIV-infected rhesus macaques
This article discusses the development and use of the anti-caspase inhibitor Q-VD-OPH in preventing AIDS disease progression in SIV-infected rhesus macaques.
View detailsContact Us
Paris Bio Santé
Faculté de Médecine
Site Cochin
24 Rue du Faubourg Saint-Jacques
75014 Paris, Île-de-France
RER B : Port-Royal
Métro Ligne 6 : Saint-Jacques
Bus : 91-83